A self-assembled protein nanocage as a universal influenza vaccine induces enhanced broadly cross-reactive immunity.

Jaeyoung Park, Sydney C Wimberley, Thomas Pho, Mariela R Rodriguez-Otero, Julie A Champion

Abstract read

In one paragraph

Article in Biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jaeyoung ParkSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, 30332, GA, USA.

Sydney C WimberleySchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, 30332, GA, USA; Bioengineering Program, Georgia Institute of Technology, Atlanta, 30332, GA, USA.

Thomas PhoSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, 30332, GA, USA; Bioengineering Program, Georgia Institute of Technology, Atlanta, 30332, GA, USA.

Mariela R Rodriguez-OteroSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, 30332, GA, USA; Bioengineering Program, Georgia Institute of Technology, Atlanta, 30332, GA, USA.

Julie A ChampionSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, 30332, GA, USA; Bioengineering Program, Georgia Institute of Technology, Atlanta, 30332, GA, USA. Electronic address: julie.champion@chbe.gatech.edu.

Funding

Self Assembled Peptide Nanoparticles as Multi-Antigen Universal Influenza VaccinesR01AI183539 · NIAID · GEORGIA INSTITUTE OF TECHNOLOGY · PI Julie Champion · 2025 to 2026

$768k

NIAID NIH HHS R01 AI183539

6 · The paper itself

Abstract

Proteins are an effective platform for vaccine design by enabling multivalent antigen presentation and stabilizing antigen structures to enhance immunogenicity. This study investigates the molecular design and ability to position antigens on self-assembled protein nanocages (SAPNs) as a universal influenza vaccine, incorporating highly conserved nucleoprotein peptides (NP55-69 and NP147-158) as CD4

Indexed as

Influenza VaccinesNanostructuresAnimalsCross ReactionsFemaleMiceNanovaccinesOrthomyxoviridae InfectionsProtein Subunit VaccinesInfluenza VaccinesNanovaccinesProtein Subunit VaccinesCross-reactive immune responseInfluenza vaccineMultivalent nanoparticleNanocageSelf-assembling protein nanoparticle

Identifiers

PMID41650589

DOI10.1016/j.biomaterials.2026.124025

PMCPMC13042213

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.